Literature DB >> 17699849

INI1 induces interferon signaling and spindle checkpoint in rhabdoid tumors.

Alexei Morozov1, Seung Jae Lee, Zhi-Kai Zhang, Velasco Cimica, David Zagzag, Ganjam V Kalpana.   

Abstract

PURPOSE: Rhabdoid tumors are rare but aggressive pediatric malignancies characterized by biallelic loss of INI1/hSNF5. Reintroduction of INI1 causes cell arrest and senescence in rhabdoid cells. Our purpose was to identify INI1-downstream genes and to determine their functional and therapeutic significance for rhabdoid tumors. EXPERIMENTAL
DESIGN: INI1 downstream targets in rhabdoid cells were identified using a cDNA microarray analysis and the expression of selected INI1 targets was confirmed by quantitative reverse transcription-PCR, Western analysis, and/or immunohistochemical analysis of rhabdoid cells and primary rhabdoid tumors. To determine the functional significance of downstream targets, activated targets of INI1 were induced and repressed targets of INI1 were knocked down (by using RNA interference) in rhabdoid cells, in the absence of INI1. Consequence of altered expression of INI1 downstream targets for rhabdoid cell survival, cell cycle, and apoptosis was assessed.
RESULTS: Microarray studies indicated that INI1 activated IFN-stimulated genes at early time points and senescence markers at late time points and repressed mitotic genes such as Polo like kinase 1 (PLK1), selectively in rhabdoid cells. Treatment of rhabdoid cells with recombinant IFNs resulted in induction of IFN-stimulated genes, G1 arrest, and flat cell formation. PLK1 was overexpressed in primary human and mouse rhabdoid tumors. RNA interference-mediated knock down of PLK1 in rhabdoid cells resulted in mitotic arrest, aberrant nuclear division, decreased survival, and induction of apoptosis.
CONCLUSIONS: Targeting downstream effectors of INI1 such as IFN pathway and mitotic genes leads to antiproliferative effects in rhabdoid cells. IFN treatment and down-modulation of PLK1 constitute potential novel therapeutic strategies for rhabdoid tumors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17699849     DOI: 10.1158/1078-0432.CCR-07-0054

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  23 in total

Review 1.  Biology and Treatment of Rhabdoid Tumor.

Authors:  James I Geller; Jacquelyn J Roth; Jaclyn A Biegel
Journal:  Crit Rev Oncog       Date:  2015

2.  Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria.

Authors:  Scott R Plotkin; Jaishri O Blakeley; D Gareth Evans; C Oliver Hanemann; Theo J M Hulsebos; Kim Hunter-Schaedle; Ganjam V Kalpana; Bruce Korf; Ludwine Messiaen; Laura Papi; Nancy Ratner; Larry S Sherman; Miriam J Smith; Anat O Stemmer-Rachamimov; Jeremie Vitte; Marco Giovannini
Journal:  Am J Med Genet A       Date:  2013-02-07       Impact factor: 2.802

Review 3.  SWI/SNF nucleosome remodellers and cancer.

Authors:  Boris G Wilson; Charles W M Roberts
Journal:  Nat Rev Cancer       Date:  2011-06-09       Impact factor: 60.716

4.  Pediatric rhabdoid tumors of kidney and brain show many differences in gene expression but share dysregulation of cell cycle and epigenetic effector genes.

Authors:  Diane K Birks; Andrew M Donson; Purvi R Patel; Alexandra Sufit; Elizabeth M Algar; Christopher Dunham; B K Kleinschmidt-DeMasters; Michael H Handler; Rajeev Vibhakar; Nicholas K Foreman
Journal:  Pediatr Blood Cancer       Date:  2013-02-04       Impact factor: 3.167

5.  Rhabdoid tumor: gene expression clues to pathogenesis and potential therapeutic targets.

Authors:  Samantha Gadd; Simone Treiger Sredni; Chiang-Ching Huang; Elizabeth J Perlman
Journal:  Lab Invest       Date:  2010-03-08       Impact factor: 5.662

6.  A G-CSF-secreting adrenal carcinoma with rhabdoid-like differentiation causing leukocytosis.

Authors:  Emil Lou; Jeremy Goodwin; David N Howell; John Hicks; L Brett Caram
Journal:  Nat Rev Urol       Date:  2009-07       Impact factor: 14.432

7.  Generation of a mouse model of atypical teratoid/rhabdoid tumor of the central nervous system through combined deletion of Snf5 and p53.

Authors:  Jessica M Y Ng; Daniel Martinez; Eric D Marsh; Zhe Zhang; Eric Rappaport; Mariarita Santi; Tom Curran
Journal:  Cancer Res       Date:  2015-09-11       Impact factor: 12.701

8.  SNF5/INI1 deficiency redefines chromatin remodeling complex composition during tumor development.

Authors:  Darmood Wei; Dennis Goldfarb; Shujie Song; Courtney Cannon; Feng Yan; Donastas Sakellariou-Thompson; Michael Emanuele; Michael B Major; Bernard E Weissman; Yasumichi Kuwahara
Journal:  Mol Cancer Res       Date:  2014-07-09       Impact factor: 5.852

Review 9.  Vulnerabilities of mutant SWI/SNF complexes in cancer.

Authors:  Katherine C Helming; Xiaofeng Wang; Charles W M Roberts
Journal:  Cancer Cell       Date:  2014-09-08       Impact factor: 31.743

10.  Recruitment of a SAP18-HDAC1 complex into HIV-1 virions and its requirement for viral replication.

Authors:  Masha Sorin; Jennifer Cano; Supratik Das; Sheeba Mathew; Xuhong Wu; Kelvin P Davies; Xuanling Shi; S-W Grace Cheng; David Ott; Ganjam V Kalpana
Journal:  PLoS Pathog       Date:  2009-06-05       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.